A Radical ’70s-Era Group Is Relaunching to Help Scientists Get Political Under Trump
By Rebecca Onion,
Slate
| 08. 29. 2018
Advocates of science are in a bad place right now. Some days, in this Second Year of Trump, scientism—a blanket defense of science as a virtuous and almost holy exercise of objectivity and rationality—feels like the only natural response to the rising darkness. But, tempting as it might be, cheerleading for capital-S “Science” can’t be the answer. Science—as historians of science and practitioners of science and technology studies readily argue—is not an objective refuge; it’s shaped by politics just like any other human endeavor. How can we acknowledge that fact while still arguing for science’s authority and value?
From 1969 through 1989, the group Science for the People tried to do just that. Its members took “science has a politics” as a philosophical starting point and then used that understanding to push for radical change. Early on, the group protested weapons labs. Members worked with the Black Panther Party, helping with their free health clinics, and with the Young Lords Organization, assisting them in offering free lead-poisoning testing services. They sent equipment to Vietnamese scientists and helped Midwestern farmworkers...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...